AlgiPharma’s medicinal alginate product gains Orphan Drug Status for Cystic Fibrosis Treatment

AlgiPharma’s medicinal product “Alginate oligosaccharide (G-block) fragment” has been designated as an orphan medicinal product for the following indication: treatment of Cystic Fibrosis. The European Medicines Agency’s Committee for Orphan Medicinal Products recommended that AlgiPharma’s application be accepted by the Commission of the European Communities. The Commission gave final approval on September 14th.

For more information contact:
Yngvar P. Berg, CEO, +47 90044903;
Astrid Hilde Myrset, Clinical Director, +47 93026094;

September 2007

AlgiPharma Established

On the initiative of FMC BioPolymer AS, AlgiPharma was established, financed and began operating as an independent company. AlgiPharma is a biopharmaceutical company that aims to develop medicinal products within the areas of respiratory diseases, wound healing and other infectious diseases.

For further information, please contact:
Arne Dessen, Chairman of Board, +47 95170278;
Yngvar P. Berg, CEO, +47 90044903;

August 2006